Full-Time
Posted on 10/31/2025
Gene editing for de-extinction of megafauna
No salary listed
Dallas, TX, USA
In Person
On-site in Dallas, TX; up to 10% travel may be required.
Colossal develops gene editing approaches to revive extinct or endangered species and restore ecological balance. It collects viable DNA samples and edits genes to rebuild traits of lost megafauna, with Woolly Mammoth as a leading project. Its technology translates into practical applications for species recovery and conservation, aiming to kickstart biodiversity and support the biology economy. Distinctive aspects include a focus on de-extinction tied to ecological restoration, leadership from Ben Lamm and George Church, and a strategy that links scientific capability with real-world ecological and economic benefits. The company’s goal is to reawaken lost wilds to help ecosystems recover and allow humanity to coexist with a healthier planet.
Company Size
201-500
Company Stage
Series C
Total Funding
$625M
Headquarters
Austin, Texas
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Spending Account/Flexible Spending Account
401(k) Company Match
Paid Parental Leave
Education Reimbursement
A second startup from Dallas billionaire Ben Lamm has achieved unicorn status with a $2 billion valuation in its latest funding round. Lamm, who also co-founded and leads Colossal Biosciences, has seen his new venture reach the milestone valuation. The company focuses on predicting biology, evolution and diseases before they occur. This marks Lamm's second startup to surpass the $1 billion valuation threshold, following his success with Colossal Biosciences.
Colossal Biosciences, which is trying to bring back the wooly mammoth with genetics tech, has spun out its AI startup Astromech at a $2 billion valuation.
Dallas-based Colossal Biosciences has secured $60 million from the United Arab Emirates to build the Colossal BioVault and World Preservation Lab at Dubai's Museum of the Future. The investment is part of Colossal's expanded Series C round, bringing total funding to over $615 million. The facility will house millions of samples representing more than 10,000 species, initially focusing on the 100 most imperiled species not currently preserved elsewhere. Using automated robotics, AI monitoring and cryopreservation technology, the project aims to create a backup system for Earth's biodiversity. The initiative addresses the threat that nearly half of Earth's species could face extinction by 2050. The Dubai facility will eventually form part of a global network of BioVaults. Visitors will observe scientists working in real time on DNA sequencing and cell line preservation.
The UAE has partnered with Colossal Biosciences to establish a laboratory and BioVault at Dubai's Museum of the Future, positioning the nation as a global leader in conservation and biodiversity protection. The initiative represents a nine-figure investment, with the UAE contributing to Colossal's recent funding round. The Colossal BioVault will preserve genetic material from over 10,000 species, initially focusing on the 100 most imperiled species not currently banked elsewhere. The facility will use automated robotics, AI monitoring and proprietary cryopreservation technology to store millions of samples. The project addresses the biodiversity crisis, with nearly half of Earth's species potentially facing extinction by 2050. The BioVault will serve as a research hub, generating genomic data and reference genomes whilst operating as a live laboratory where visitors can witness preservation work in real time.
Colossal Biosciences, the world’s de-extinction company, today announced its acquisition of Viagen Pets and Equine, the global leader and expert in animal cl...